Dr. Avak Kahvejian, Founding CEO of Cellarity, explains their new approach to discovering drugs by using AI to look at how cells behave as a whole, rather than focusing on one part of the problem. This approach could lead to faster development of better treatments, such as a pill for sickle cell disease.

This week on Biotech Nation, Paul Hastings, CEO of Nkarta and former chair of BIO—the Biotechnology Innovation Organization—discusses the impact of cuts to research funding and stepping away from recommending vaccines—what this means for you and the biotech industry. 

This week on BioTech Nation, Dr. Mark Kendall, CEO of WearOptimo, tells us about progress with their new wearable. You could be dehydrated and not even know it … And exactly how hydrated are you right now, anyway? The old “if you’re thirsty, drink something” turns out to be a little too late. 

This week on BioTech Nation, Dr. Steve Harr, CEO of Sana Biotechnology, talks about their progress in Type I diabetics, in particular. The New England Journal of Medicine publishes early success with Sana Biotechnology's engineered insulin-producing cells without immunosuppressant drugs.

This week on BioTech Nation, Dr. Neal Kassell, founder of the Focused Ultrasound Foundation, introduces us to a powerful, non-invasive technology that’s already changing lives, and it doesn’t involve surgery, injections, or pills. 

This week on BioTech Nation, Dr. Raza Bokhari, CEO of Medicus Pharma, shares a new non-surgical treatment approach for basal cell carcinoma, the most common form of skin cancer. Their novel microneedle patch delivers a powerful cancer drug directly into the skin, avoiding the scarring, cost, and discomfort of Mohs surgery. With promising phase 2 trials underway in the US and Europe, this could change the way we treat millions of skin cancer cases every year. 

This week on BioTech Nation, Dr. Eric Topol returns to continue his conversation on, "Super Agers … An Evidenced-Based Approach to Longevity", his evidence-based approach to living longer, healthier lives. He shares why longevity must be accessible to everyone, not just the wealthy, and how new tools like AI, personalized diagnostics, and even gut hormones are reshaping the future of health. 

This week on BioTech Nation, Dr. Eric Topol, professor and Executive Vice President at Scripps Research and author of "Super Agers … An Evidenced-Based Approach to Longevity", breaks down what science really says about aging well and what is just marketing. From immune-boosting cell therapy to the myth of magic longevity pills, Dr. Topol explains how evidence-based prevention, personalized health data, and AI are changing the future of aging. 

This week on Biotech Nation, Dr. Neil Kumar, founder and CEO of BridgeBio Pharma. Dr. Kumar emphasizes that genetic diseases, particularly Mendelian diseases caused by single gene mutations, are solvable due to advancements in genetic measurement and understanding. He discusses BridgeBio Pharma's innovative corporate structure, which consists of multiple specialized companies under a centralized infrastructure to efficiently tackle various genetic diseases. This model allows for focused expertise on individual conditions while sharing common resources. Dr. Kumar highlights the company's commitment to using diverse therapeutic modalities, such as small molecules and gene therapies, to develop treatments that address the underlying causes of these diseases.